Skip to main content
. 2018 Oct 1;42(6):3371–3385. doi: 10.3892/ijmm.2018.3907

Figure 7.

Figure 7

Oltipraz activates the Nrf2 pathway and increases cellular antioxidant activity in PC12 cells. (A) An optimal concentration of D-gal was selected using a CCK-8 test. (B) Protein expression of Nrf2; (C) Nrf2 siRNA transfection decreased the protein expression of Nrf2 in PC12 cells. (D) Nrf2 siRNA transfection decreased the expression of Nrf2 target genes in PC12 cells. (E) A maximal cytoprotective concentration of oltipraz was selected using the CCK-8 test. (F) mRNA levels of NQO1, HO-1 and MnSOD in the control and oltipraz groups. (G) ROS levels were measured in the treated cells using DCFH-DA staining and analyzed by flow cytometry; (H) graph shows ROS levels. For all experiments, *P<0.05, **P<0.01 and ***P<0.001. The data are presented as the mean ± standard deviation. Nrf2, NF-E2-related factor 2; D-gal, D-galactose; siRNA, small interfering RNA; CCK-8, Cell Counting Kit-8; ROS, reactive oxygen species; DCFH-DA, dichlorodihydrofluorescein diacetate; NQO1, NAD(P)H quinone oxidoreductase 1; HO-1, heme oxygenase-1; MnSOD, manganese superoxide dismutase; DMSO, dimethyl sulfoxide.